⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22402145 | 1.00 | — | — | |
| SCHEMBL23562329 | 1.00 | MGLL (0.53) | — | |
| SCHEMBL24109524 | 0.96 | — | — | |
| SCHEMBL19977106 | 0.73 | — | — | |
| SCHEMBL24974930 | 0.72 | — | — | |
| SCHEMBL18949241 | 0.69 | MGLL (0.60) | — | |
| SCHEMBL5337164 | 0.69 | MGLL (0.60) | — | |
| SCHEMBL18581640 | 0.69 | MGLL (0.60) | — | |
| SCHEMBL5328404 | 0.69 | MGLL (1.00) | — | |
| SCHEMBL19977094 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108686223-A | A kind of preparation carrying medicine composite material by the external chitosan tubulose mesoporous silicon oxide of disulfide bond | 常州大学 | 2018-10-23 | — | — | CN | claimed |
| US-20100021480-A1 | BIOACTIVE SUBSTANCE-BLOOD PROTEIN CONJUGATE AND STABILIZATION OF A BIOACTIVE SUBSTANCE USING THE SAME | PEPTRON CO., LTD (KR) | 2010-01-28 | — | — | US | claimed |
| EP-1948676-A1 | BIOACTIVE SUBSTANCE-BLOOD PROTEIN CONJUGATE AND STABILIZATION OF A BIOACTIVE SUBSTANCE USING THE SAME | Peptron Co., Ltd. (KR) | 2008-07-30 | — | — | EP | claimed |
| WO-2007049940-A1 | BIOACTIVE SUBSTANCE-BLOOD PROTEIN CONJUGATE AND STABILIZATION OF A BIOACTIVE SUBSTANCE USING THE SAME | PEPTRON CO., LTD (KR) | 2007-05-03 | — | — | WO | claimed |
| WO-2007049941-A1 | BIOACTIVE SUBSTANCE CARRIER FOR IN VIVO STABLE DELIVERY TEHREOF, CONJUGATE CONTAINING THE SAME, AND METHOD OF IN VIVO STABLE DELIVERY OF THE BIOACTIVE SUBSTANCE | PEPTRON CO., LTD (KR) | 2007-05-03 | — | — | WO | claimed |
| US-20230234955-A1 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS | ARRAY BIOPHARMA INC (US) | 2023-07-27 | — | — | US | disclosed |
| CN-104448700-B | Resin combination | 味之素株式会社 | 2019-01-22 | — | — | CN | disclosed |
| CN-109196008-A | Reactive polysiloxane and polymerizable composition, polymerizable composition comprising the reactive polysiloxane | 日产化学株式会社 | 2019-01-11 | — | — | CN | disclosed |
| US-20170114067-A1 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS | ARRAY BIOPHARMA, INC. | 2017-04-27 | — | — | US | disclosed |
| US-9598423-B2 | Substituted 4,5,6,7-tetrahydropyrazolo[1,5-A]pyrazine derivatives as casein kinase 1 D/E inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-03-21 | — | — | US | disclosed |
| CN-104448700-A | Resin composition | AJINOMOTO KK | 2015-03-25 | — | — | CN | disclosed |
| US-20100021480-A1 | BIOACTIVE SUBSTANCE-BLOOD PROTEIN CONJUGATE AND STABILIZATION OF A BIOACTIVE SUBSTANCE USING THE SAME | PEPTRON CO., LTD (KR) | 2010-01-28 | — | — | US | disclosed |
| EP-1948676-A1 | BIOACTIVE SUBSTANCE-BLOOD PROTEIN CONJUGATE AND STABILIZATION OF A BIOACTIVE SUBSTANCE USING THE SAME | Peptron Co., Ltd. (KR) | 2008-07-30 | — | — | EP | disclosed |
| WO-2007049940-A1 | BIOACTIVE SUBSTANCE-BLOOD PROTEIN CONJUGATE AND STABILIZATION OF A BIOACTIVE SUBSTANCE USING THE SAME | PEPTRON CO., LTD (KR) | 2007-05-03 | — | — | WO | disclosed |
| WO-2007049940-A1 | BIOACTIVE SUBSTANCE-BLOOD PROTEIN CONJUGATE AND STABILIZATION OF A BIOACTIVE SUBSTANCE USING THE SAME | PEPTRON CO., LTD (KR) | 2007-05-03 | — | — | WO | disclosed |
| WO-2007049941-A1 | BIOACTIVE SUBSTANCE CARRIER FOR IN VIVO STABLE DELIVERY TEHREOF, CONJUGATE CONTAINING THE SAME, AND METHOD OF IN VIVO STABLE DELIVERY OF THE BIOACTIVE SUBSTANCE | PEPTRON CO., LTD (KR) | 2007-05-03 | — | — | WO | disclosed |